A Genome-Wide CRISPR/Cas9 Screen Reveals Epigenetic Immune Evasion Mechanisms in HPV+HNSCC

<u>Nicholas S. Giacobbi^{1,2}</u>, Lexi Vu¹, Shreya Mullapudi^{1,2}, Canchai Yang¹, Hyun Hee Lee¹, Mohamed Khalil¹, Andrew Olive¹, and Dohun Pyeon¹

¹ Department of Microbiology and Molecular Genetics, Michigan State University, East Lansing, MI

² College of Osteopathic Medicine, Michigan State University, East Lansing, MI

Clinical Case



Pt: 69 M

CC: R throat discomfort and enlarged lymph node for >3 months

Hx/PE/Labs: Enlarged R palatine lymph node with squamous cell carcinoma detected; p16+

Dx: Human papillomavirus (+) Head and Neck Squamous Cell Carcinoma (*HPV*+*HNSCC*)

Tx: Surgical dissection and Radiation

Remission for ~4 years

Cancer Relapses with evidence of metastasis

Patient was admitted to palliative care

PMID: 32695371 Photo: 2023 Providence

Poor prognosis for ~20% patients (HPV+HNSCC)

→ Treatment non-responders, recurrent/metastatic disease

Lack of subsequent treatment options

PMID: 32695371 Photo: 2023 Providence

How do we help these patients?





Genome-wide screens revealed **Epigenetic modifiers** negatively regulate MHC-I



Healthy Cells

Genome-wide screens revealed **Epigenetic modifiers** negatively regulate MHC-I



Normal MHC-I expression









Decreased MHC-I expression













HPV+ Cancer Cells



HPV+ Cancer Cells



Deplete ~20,000 Genes Using CRISPR/Cas9



With Dr. Andrew Olive and Dr. Mohamed Khalil





With Dr. Andrew Olive and Dr. Mohamed Khalil



Top Common Negative Regulators Among Screens



nown epigenetic regulators of gene transcriptior (**PRC2 or SAGA complexes**)

The SAGA Complex



The SAGA Complex





Histone Acetyltransferase

KAT2A is a regulator of transcription

The SAGA Complex is a negative regulator of MHC-I



Inhibition of KAT2A upregulates MHC-I Expression



Inhibition of KAT2A upregulates MHC-I Expression



Inhibition of KAT2A upregulates MHC-I Expression





PRC2.1 is a negative regulator of MHC-I







Inhibition of PRC2 upregulates MHC-I Expression





Pharmacologic Validation and Drug Intervention



Epigenetic inhibitors upregulate MHC-I Expression





KAT2A controls PRC2 transcription



Inhibition of KAT2A increases MHC-I and decreases PRC2 expression



Ingenuity Pathway Analysis: Predicted Gene Regulators



KAT2A binds to E2Fs



KAT2A fine-tunes E2F mediated transcription of PRC2 genes



PRC2 gene promoters

Epigenetic regulators KAT2A (SAGA) and PRC2 work in concert to repress MHC-I

Genetic and pharmacologic inhibition of KAT2A or PRC2 restored MHC-I

KAT2A and PRC2 may be **novel targets** for **treatment** of HPV+HNSCC



Acknowledgements



Pyeon Lab:

Dr. Dohun Pyeon Dr. Mohamed Khalil Hyomin Son Dr. Hyun Hee Lee Canchai Yang Lexi Vu Shreya Mullapudi Smriti Chadha Harrison Nabors Prerna Chahal Will Eckerman Evelyn Gomez Saloni Shah Anthony Schulte Alex Wahl

Jessica de Assis







Committee

Dr. Kathleen Gallo Dr. Eran Andrechek Dr. Hua Xiao Dr. Karen Liby Dr. Yasser Aldhamen

> **Software:** Illustrations made with Biorender IPA Analysis: Qiagen

Collaborators

Dr. Andrew Olive John Vusich

> *Title Slide:* Henry Siddons Mowbray, **Destiny**, 1896 Museum of Fine Arts, Boston MA

SAGA complex is predominant network of MHC-I downregulation



Garcinol upregulates MHC-I in HPV+HNSCC



How is E2F downregulating MHC-I?

EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer

Adrian P Bracken¹, Diego Pasini, Maria Capra, Elena Prosperini, Elena Colli, Kristian Helin EMBO J. **2003** Oct 15;22(20):5323-35.

Identification of the polycomb group protein SU(Z)12 as a potential molecular target for human cancer therapy

Antonis Kirmizis¹, Stephanie M Bartley, Peggy J Farnham Mol Cancer Ther. **2003** Jan;2(1):113-21.



EMBO



Regulators of MHC-I Expression



KAT2A expression negatively correlates with immune cell infiltration



Correlations based on TCGA datasets via TIMER2.0